felin
infecti
periton
fip
fatal
diseas
domest
nondomest
felid
caus
felin
coronaviru
fcov
current
effect
vaccin
avail
prevent
diseas
search
agent
may
prove
clinic
effect
fcov
infect
compound
screen
antivir
activ
local
fcov
strain
feli
catu
whole
cell
result
show
galanthu
nivali
agglutinin
gna
nelfinavir
effect
inhibit
fcov
replic
amount
viru
preinocul
test
cell
increas
mimic
high
viral
load
present
target
cell
fip
cat
gna
nelfinavir
lost
inhibitori
effect
howev
two
agent
ad
togeth
fcovinfect
cell
synergist
antivir
effect
defin
complet
blockag
viral
replic
observ
result
suggest
combin
use
gna
nelfinavir
therapeut
potenti
prophylaxi
treatment
cat
earlydiagnos
fip
felin
infecti
periton
fip
fatal
diseas
domest
nondomest
felid
caus
felin
coronaviru
fcov
hartmann
immunopathogen
diseas
cat
similar
sever
acut
respiratori
syndrom
sar
human
character
intens
inflammatori
respons
compromis
normal
physiolog
function
contribut
progress
debilit
condit
weight
loss
fever
system
diseas
paltrinieri
perlman
dandekar
although
fcov
known
year
caus
pathogen
fip
immunopathogen
natur
diseas
prevent
success
vaccin
trial
christianson
et
al
scott
stoddart
et
al
vennema
et
al
b
sever
studi
attempt
identifi
effect
antifcov
treatment
fipdiseas
cat
hartmann
ritz
ribavirin
nucleosid
analogu
shown
inhibit
growth
fcov
vitro
barlough
scott
weiss
oostromram
nevertheless
side
effect
hinder
clinic
applic
weiss
et
al
recent
sever
antivir
agent
sarscoronaviru
sarscov
identifi
includ
carbohydratebind
agent
keyaert
et
al
hiv
proteas
inhibitor
yamamoto
et
al
antipsychot
drug
ho
et
al
zhang
yap
anthraquinon
compound
ho
et
al
nucleosid
analogu
tan
et
al
interferon
subtyp
sarscov
inhibitor
commerci
avail
antivir
agent
might
promis
candid
control
treat
fcov
infect
cat
carri
present
studi
success
identifi
two
compound
act
effect
recent
isol
fcov
strain
found
combin
use
agent
show
synergist
antivir
effect
studi
compound
use
base
pharmacolog
activ
antivir
agent
group
nucleosid
analogu
acyclovir
idoxuridin
ribavirin
ii
proteas
inhibitor
atazanavir
indinavir
lopinavirritonavir
nelfinavir
saquinavir
iii
revers
transcriptas
inhibitor
efavirenz
lamivudin
lamivudinezidovudin
nelvirapin
stavudin
iv
compound
activ
emodin
galanthu
nivali
agglutinin
atrasheuskaya
et
al
promazin
detail
compound
test
list
tabl
gna
dissolv
doubl
distil
water
solvent
compound
dimethyl
sulfoxid
feli
catu
whole
cell
kindli
provid
professor
peter
j
rottier
utrecht
univers
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
iuml
penicillin
gml
streptomycin
co
c
fcov
strain
recent
isol
pleural
effus
kitten
cocultiv
method
lin
et
al
local
fcov
strain
type
ii
viru
sequenc
partial
spike
gene
deposit
genbank
access
number
lin
et
al
virus
use
studi
assess
antivir
activ
came
stock
passag
time
cell
viabil
evalu
bromid
mtt
assay
briefli
cell
per
well
seed
plate
h
incub
c
variou
concentr
compound
ad
confluent
cell
monolay
incub
h
highest
concentr
test
compound
indic
fig
mtt
ad
well
final
concentr
mgml
h
incub
c
medium
contain
mtt
remov
cell
lyse
l
lysi
buffer
follow
overnight
incub
room
temperatur
absorb
valu
nm
measur
wavelength
nm
use
micropl
reader
cell
viabil
calcul
express
od
treat
cellsod
untreat
cell
concentr
compound
reduc
cell
viabil
cc
determin
use
mtt
assay
base
result
obtain
cell
viabil
test
highest
concentr
show
less
cytotox
cell
chosen
test
compound
tabl
chosen
concentr
premix
multipl
infect
moi
incub
c
h
monitor
effect
preentri
step
mixtur
compound
viru
inocul
cell
plate
h
adsorpt
follow
replac
mixtur
dmem
fb
monitor
effect
entri
step
cope
fastgrow
natur
strain
lin
et
al
infect
cell
fix
h
postinfect
formalin
stain
crystal
violet
cytopath
effect
cpe
character
format
polykaryocyt
number
polykaryocyt
present
whole
well
count
invert
microscop
agent
abl
significantli
inhibit
format
cpe
foci
appli
evalu
antivir
effect
concentrationdepend
manner
four
concentr
show
cytotox
effect
compound
chosen
premix
moi
h
incub
c
mixtur
inocul
cell
plate
follow
h
adsorpt
mixtur
remov
dmem
fb
ad
h
postinfect
cell
fix
stain
cpe
count
inhibitori
effect
effect
compound
detect
use
microtitr
infectivityinhibit
assay
compound
twofold
serial
dilut
premix
viru
moi
inocul
cell
examin
h
postinfect
presenc
viral
cpe
ic
calcul
use
previous
describ
method
reed
muench
cell
infect
viru
moi
h
adsorpt
viru
remov
cell
maintain
fresh
dmem
contain
fb
effect
compound
alon
combin
h
postinfect
cultur
super
natant
harvest
store
c
evalu
infect
cell
subject
mtt
assay
assess
cell
viabil
infect
cultur
supernat
evalu
plaqu
assay
describ
method
lin
et
al
viral
inoculum
aspir
overlaid
methylcellulos
dmem
supplement
fb
three
day
incub
cell
fix
stain
plaqu
count
visual
data
compound
present
mean
standard
deviat
student
ttest
use
comparison
treat
untreat
group
p
valu
consid
statist
highli
signific
highli
signific
respect
twoway
analysi
varianc
use
test
effect
interact
two
compound
p
valu
consid
statist
signific
posit
effect
interact
two
compound
cell
surviv
evalu
three
day
treatment
variou
concentr
compound
fig
test
concentr
compound
appear
nontox
slightli
toxic
cell
contrari
atazanavir
lopinavirritonavir
nelfinavir
saquinavir
efavirenz
emodin
dramat
cytotox
effect
observ
cc
valu
compound
list
tabl
cell
display
typic
cpe
character
gener
multinucl
giant
cell
fig
base
viabil
result
highest
concentr
everi
test
compound
show
less
cytotox
chosen
test
antivir
effect
among
compound
test
gna
nelfinavir
significantli
inhibit
number
cpe
foci
induc
infect
fcov
compar
untreat
group
tabl
fig
ic
valu
gna
nelfinavir
moi
pfuml
nm
respect
tabl
gna
potent
nelfinavir
inhibit
fcov
replic
determin
whether
antivir
effect
concentrationdepend
four
concentr
nelfinavir
gna
test
highest
concentr
nelfinavir
significantli
block
induct
cpe
foci
p
fig
gna
contrast
show
strong
inhibitori
activ
four
concentr
antivir
effect
concentrationdepend
fig
experi
describ
establish
effect
gna
nelfinavir
preentri
entri
step
viral
infect
next
sought
determin
whether
compound
effect
postentri
step
environ
high
viral
load
found
fip
cat
kipar
et
al
mimic
target
cell
present
tissu
diseas
anim
preinfect
cell
treat
antivir
compound
cell
infect
moi
pfuml
cell
treat
either
one
antivir
compound
h
mtt
plaqu
assay
simultan
perform
examin
cell
damag
caus
viral
replic
presenc
infecti
viru
cultur
supernat
despit
lack
signific
cell
damag
h
postinocul
supplementari
data
result
plaqu
assay
reveal
treatment
either
gna
nelfinavir
alon
highest
concentr
nm
respect
fig
supplementari
data
complet
inhibit
fcov
replic
howev
synergist
antivir
effect
observ
agent
ad
simultan
fcov
replic
complet
block
six
combin
ie
nelfinavir
gna
nm
nelfinavir
gna
nm
fig
supplementari
data
rule
possibl
cytotox
due
combin
two
compound
mtt
assay
perform
effect
combin
observ
cytotox
found
effect
combin
data
shown
test
cell
infect
low
concentr
fcov
nelfinavir
gna
prove
effect
inhibit
viral
replic
nelfinavir
inhibitor
proteas
strong
vivo
activ
drug
safe
wide
use
hivinfect
patient
lewi
et
al
antivir
effect
nelfinavir
coronavirus
investig
sarscov
infect
yamamoto
et
al
similar
find
nelfinavir
inhibit
sarscov
strain
compound
found
significantli
block
replic
fcov
ic
nelfinavir
sarscov
concentr
appear
lower
fcov
differ
efficaci
might
result
low
amino
acid
sequenc
homolog
two
virus
sarscov
fra
genbank
access
number
fcov
access
number
put
proteas
ie
target
molecul
nelfinavir
furthermor
residu
sarscov
identifi
interact
sever
hiv
proteas
inhibitor
includ
nelfinavir
rajnarayanan
et
al
ident
correspond
residu
fcov
might
also
main
factor
contribut
high
si
data
nelfinavir
sarscov
comparison
fcov
besid
differ
cell
use
assay
clinic
trial
use
nelfinavir
mean
control
fcov
infect
reveal
obvious
side
effect
eg
diarrhea
nausea
occasion
seen
human
hiv
patient
take
agent
observ
clinic
healthi
fcovshed
cat
receiv
dosag
mg
mgkgday
per
os
preliminari
find
rais
hope
use
futur
clinic
practic
first
studi
demonstr
inhibitor
proteas
activ
effect
block
replic
fcov
gna
carbohydratebind
agent
exhibit
antivir
effect
bind
two
glycosyl
envelop
glycoprotein
spike
membran
protein
coronavirus
van
der
meer
et
al
recent
studi
vitro
shown
gna
strongli
inhibit
fcov
serotyp
ii
preentri
step
van
der
meer
et
al
cell
viabil
test
show
gna
could
use
safe
cell
broader
concentr
rang
nelfinavir
tabl
agent
show
antivir
activ
local
type
ii
fcov
strain
concentrationdepend
manner
appli
preentri
step
fig
aim
studi
search
effect
antifcov
agent
futur
clinic
applic
therefor
also
examin
antivir
effect
compound
postentri
step
cell
preinocul
high
concentr
viru
moi
order
mimic
environ
infect
cell
insid
bodi
fip
cat
condit
two
effect
compound
lost
antifcov
activ
use
surpris
given
antivir
effect
nelfinavir
demonstr
postentri
step
sarscov
infect
yamamoto
et
al
antivir
activ
nelfinavir
could
assay
due
cytotox
compound
higher
concentr
tabl
fact
gna
lost
antivir
effect
cell
preinocul
fcov
unexpect
compound
work
primarili
step
viral
attach
keyaert
et
al
use
togeth
two
compound
effect
inhibit
product
infecti
fcov
synergist
effect
may
reflect
compound
complementari
mechan
action
nelfinavir
affect
postentri
step
gna
affect
preentri
step
specul
gna
nelfinavir
use
clinic
follow
prevent
fip
highrisk
group
eg
fullsibl
litterm
fip
kitten
addi
et
al
fcovshed
popul
live
multiplecat
household
ii
treatment
earlystag
fip
sinc
fip
cat
alway
show
chronic
secondari
fever
accompani
increas
viral
rna
plasma
andor
white
blood
cell
death
de
grootmijn
et
al
case
fip
diagnos
earli
administr
effect
antivir
agent
may
provid
chanc
prevent
secondari
viremia
trigger
fatal
stage
diseas
system
applic
gna
might
provok
antibodi
respons
lead
inact
compound
primari
antibodi
respons
gener
appear
week
antigen
stimul
murphi
et
al
futur
therapeut
protocol
need
design
administ
gna
effici
dose
within
first
week
togeth
effect
antivir
agent
like
nelfinavir
found
studi
other
current
test
proper
combin
effect
agent
target
differ
stage
viral
replic
cocktail
therapi
like
treat
hiv
human
patient
may
avail
near
futur
cat
suffer
fip
known
side
effect
nelfinavir
mild
diarrhea
previous
observ
hiv
patient
kaldor
et
al
wherea
side
effect
gna
report
sinc
fip
immunopathogen
diseas
treatment
aim
control
viral
replic
alon
suffici
success
supplementari
treatment
may
includ
antivir
drug
interferon
immunosuppress
therapi
perhap
cytokin
antagonist
tumor
necrosi
factor
alpha
tnfalpha
antagonist
antagonist
shown
reduc
mortal
anoth
immunemedi
diseas
dengu
viru
infect
atrasheuskaya
et
al
reagent
may
also
effect
fip
cat
given
increas
level
tnfalpha
note
fip
cat
takano
et
al
b
studi
demonstr
synergist
antivir
effect
gna
nelfinavir
inhibit
fcov
replic
infect
cell
result
suggest
combin
use
two
agent
potenti
therapi
prevent
treat
fip
cat
long
diagnosi
made
earli
